Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-Naïve and ESA-Treated chronic kidney disease patients with renal anemia

Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2010, Pages 507-520

  Chanu, Pascal ^b   Gieschke, Ronald ^a   Charoin, Jean Eric ^a   Pannier, Anne ^a   Reigner, Bruno ^a  

^a A Certara Company   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

C.E.R.A.; Modeling; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ERYTHROCYTE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIMULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HALF-LIFE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 77951167067     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009343931     Document Type: Article

References (19)

1. Sheiner LB, Steimer JL Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000 ; 40: 67-96.
2. Derendorf H., Lesko LJ, Chaikin P., et al. Pharmacokinetic/ pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 2000 ; 40: 1399-1418.
3. Locatelli F., Aljama P., Bárány P., et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004 ; 19 (suppl 2). ii1 - ii47. (Pubitemid 29401692)
4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006 ; 47 (suppl 3). S1 - S146.
5. Jarsch M., Brandt M., Lanzendörfer M., Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008 ; 81: 63-69. (Pubitemid 350124538)
6. Macdougall IC C.E.R.A. (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005 ; 4: 436-440.
7. Macdougall IC, Eckardt KU Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006 ; 368: 947-953.
8. Klinger M., Arias M., Vargemezis V., et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007 ; 50: 989-1000. (Pubitemid 350122810)
9. Levin NW, Fishbane S., Cañedo FV, et al. MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007 ; 370: 1415-1421. (Pubitemid 47576167)
10. Sulowicz W., Locatelli F., Ryckelynck JP, et al. PROTOS study investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007 ; 2: 637-646.
11. Canaud B., Mingardi G., Braun J., et al. on behalf of the STRIATA study investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008 ; 23: 3654-3661.
12. Macdougall IC, Walker R., Provenzano R., et al. ARCTOS study investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008 ; 3: 337-347.
13. Spinowitz B., Coyne DW, Lok CE, et al. RUBRA study investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008 ; 28: 280-289.
14. Davidian M., Giltinan DM Nonlinear models for repeated measurement data. In: Cox DR, Hinkley DV, Keiding N, Reid N, Rubin DB, Silverman BW, eds. Monographs in Statistics and Applied Probability. London: Chapman & Hill; 1995: 108-109.
15. Krzyzanski W., Jusko WJ, Wacholtz MC, Minton N., Cheung WK Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005 ; 26: 295-306. (Pubitemid 41278636)
16. Krzyzanski W., Ramakrishnan R., Jusko WJ Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm. 1999 ; 27: 467-489. (Pubitemid 30497279)
17. Locatelli F., Villa G., de Francisco AL, et al. BA16286 study investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007 ; 23: 969-979. (Pubitemid 46799579)
18. Drüeke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001 ; 16 (suppl 7). 25-28. (Pubitemid 33062119)
19. Uehlinger DE, Gotch FA, Sheiner LB A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992 ; 51: 76-89.